Literature DB >> 27152859

Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging.

Shuya Yano1,2,3, Kiyoto Takehara1,2,3, Ming Zhao1, Yuying Tan1, Qinghong Han1, Shukuan Li1, Michael Bouvet2, Toshiyoshi Fujiwara3, Robert M Hoffman1,2.   

Abstract

We previously reported real-time monitoring of cell cycle dynamics of cancer cells throughout a live tumor intravitally using a fluorescence ubiquitination cell cycle indicator (FUCCI). Approximately 90% of cancer cells in the center and 80% of total cells of an established tumor are in G0/G1 phase. Longitudinal real-time FUCCI imaging demonstrated that cytotoxic agents killed only proliferating cancer cells at the surface and, in contrast, and had little effect on the quiescent cancer cells. Resistant quiescent cancer cells restarted cycling after the cessation of chemotherapy. Thus cytotoxic chemotherapy which targets cells in S/G2/M, is mostly ineffective on solid tumors, but causes toxic side effects on tissues with high fractions of cycling cells, such as hair follicles, bone marrow and the intestinal lining. We have termed this phenomenon tumor intrinsic chemoresistance (TIC). We previously demonstrated that tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) decoyed quiescent cancer cells in tumors to cycle from G0/G1 to S/G2/M demonstrated by FUCCI imaging. We have also previously shown that when cancer cells were treated with recombinant methioninase (rMETase), the cancer cells were selectively trapped in S/G2, shown by cell sorting as well as by FUCCI. In the present study, we show that sequential treatment of FUCCI-expressing stomach cancer MKN45 in vivo with S. typhimurium A1-R to decoy quiescent cancer cells to cycle, with subsequent rMETase to selectively trap the decoyed cancer cells in S/G2 phase, followed by cisplatinum (CDDP) or paclitaxel (PTX) chemotherapy to kill the decoyed and trapped cancer cells completely prevented or regressed tumor growth. These results demonstrate the effectiveness of the praradigm of "decoy, trap and shoot" chemotherapy.

Entities:  

Keywords:  FUCCI; Salmonella typhimurium A1-R; cancer; cell-cycle; cisplatinum; decoy; methioninase; nude mice; paclitaxel; stomach cancer; trap

Mesh:

Substances:

Year:  2016        PMID: 27152859      PMCID: PMC4957602          DOI: 10.1080/15384101.2016.1181240

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  77 in total

1.  Matching targets for selective cancer therapy.

Authors:  Mikhail V Blagosklonny
Journal:  Drug Discov Today       Date:  2003-12-15       Impact factor: 7.851

2.  Antagonistic drug combinations that select against drug resistance: from bacteria to cancer.

Authors:  Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2007-07       Impact factor: 4.742

Review 3.  Death through a tragedy: mitotic catastrophe.

Authors:  H Vakifahmetoglu; M Olsson; B Zhivotovsky
Journal:  Cell Death Differ       Date:  2008-04-11       Impact factor: 15.828

Review 4.  How cancer could be cured by 2015.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2005-02-21       Impact factor: 4.534

5.  Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity.

Authors:  Fang Liu; Lei Zhang; Robert M Hoffman; Ming Zhao
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

6.  Synchronization of L1210 leukemia with hydroxyurea infusion and the effect of subsequent pulse dose chemotherapy.

Authors:  R E Moran; M J Straus
Journal:  Cancer Treat Rep       Date:  1980-01

7.  Visualizing spatiotemporal dynamics of multicellular cell-cycle progression.

Authors:  Asako Sakaue-Sawano; Hiroshi Kurokawa; Toshifumi Morimura; Aki Hanyu; Hiroshi Hama; Hatsuki Osawa; Saori Kashiwagi; Kiyoko Fukami; Takaki Miyata; Hiroyuki Miyoshi; Takeshi Imamura; Masaharu Ogawa; Hisao Masai; Atsushi Miyawaki
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

8.  Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice.

Authors:  Chisa Nagakura; Katsuhiro Hayashi; Ming Zhao; Kensuke Yamauchi; Norio Yamamoto; Hiroyuki Tsuchiya; Katsuro Tomita; Michael Bouvet; Robert M Hoffman
Journal:  Anticancer Res       Date:  2009-06       Impact factor: 2.480

9.  Improved retroviral suicide gene transfer in colon cancer cell lines after cell synchronization with methotrexate.

Authors:  Laetitia Finzi; Aurore Kraemer; Claude Capron; Severine Noullet; Diane Goere; Christophe Penna; Bernard Nordlinger; Josette Legagneux; Jean-Fançois Emile; Robert Malafosse
Journal:  J Exp Clin Cancer Res       Date:  2011-10-04

10.  Intraperitoneal administration of tumor-targeting Salmonella typhimurium A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice.

Authors:  Yasunori Matsumoto; Shinji Miwa; Yong Zhang; Ming Zhao; Shuya Yano; Fuminari Uehara; Mako Yamamoto; Yukihiko Hiroshima; Makoto Toneri; Michael Bouvet; Hisahiro Matsubara; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Oncotarget       Date:  2015-05-10
View more
  24 in total

1.  Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.

Authors:  Kei Kawaguchi; Kentaro Miyake; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Thinzar M Lwin; Takashi Higuchi; Tasuku Kiyuna; Masuyo Miyake; Hiromichi Oshiro; Michael Bouvet; Michiaki Unno; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-05-21       Impact factor: 4.534

2.  Bugs as Cancer Drugs: Challenges and Opportunities.

Authors:  Phillip J Daschner; Avraham Rasooly; Jeffrey D White
Journal:  Mol Cell Biol       Date:  2019-07-16       Impact factor: 4.272

3.  Cell-cycle-dependent drug-resistant quiescent cancer cells induce tumor angiogenesis after chemotherapy as visualized by real-time FUCCI imaging.

Authors:  Shuya Yano; Kiyoto Takehara; Hiroshi Tazawa; Hiroyuki Kishimoto; Yasuo Urata; Shunsuke Kagawa; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

4.  Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Shukuan Li; Qinghong Han; Yuying Tan; Ming Zhao; Yunfeng Li; Scott D Nelson; Sarah M Dry; Arun S Singh; Irmina A Elliott; Tara A Russell; Mark A Eckardt; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-04-10       Impact factor: 4.534

5.  Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models.

Authors:  Kei Kawaguchi; Kentaro Miyake; Ming Zhao; Tasuku Kiyuna; Kentaro Igarashi; Masuyo Miyake; Takashi Higuchi; Hiromichi Oshiro; Michael Bouvet; Michiaki Unno; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-09-19       Impact factor: 4.534

6.  Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma.

Authors:  Lin Xin; Hou-Ting Zhang; Wei-Feng Yang; Yi-Fan Li; Chuan Liu
Journal:  Biosci Rep       Date:  2018-01-30       Impact factor: 3.840

7.  Cell mass-dependent expression of an anticancer protein drug by tumor-targeted Salmonella.

Authors:  Kwangsoo Kim; Sa-Young Min; Ho-Dong Lim; Sung-Hwan You; Daejin Lim; Jae-Ho Jeong; Hyun-Ju Kim; Joon Haeng Rhee; Kyeongil Park; Minsang Shin; Geun-Joong Kim; Jung-Joon Min; Hyon E Choy
Journal:  Oncotarget       Date:  2018-01-05

8.  Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium.

Authors:  Daejin Lim; Kwang Soo Kim; Hyunju Kim; Kyong-Cheol Ko; Jae Jun Song; Jong Hyun Choi; Minsang Shin; Jung-Joon Min; Jae-Ho Jeong; Hyon E Choy
Journal:  Oncotarget       Date:  2017-06-06

9.  Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Shukuan Li; Qinghong Han; Yuying Tan; Tasuku Kiyuna; Kentaro Miyake; Takashi Murakami; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2017-08-12

10.  Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions.

Authors:  M Gabriela Kramer; Martín Masner; Fernando A Ferreira; Robert M Hoffman
Journal:  Front Microbiol       Date:  2018-01-23       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.